Kalkine Media ASX Share Market News & Research
Watchlist Sign Up/Login
https://kalkinemedia.com/resources/assets/public/img/flags/au.png AUS
https://kalkinemedia.com/resources/assets/public/img/flags/nz.png NZ
https://kalkinemedia.com/resources/assets/public/img/flags/uk.png UK
https://kalkinemedia.com/resources/assets/public/img/flags/ca.png CA
https://kalkinemedia.com/resources/assets/public/img/flags/us.png USA
https://kalkinemedia.com/resources/assets/public/img/flags/fr.png FRA
https://kalkinemedia.com/resources/assets/public/img/flags/de.png GER
https://kalkinemedia.com/resources/assets/public/img/flags/es.png ESP
https://kalkinemedia.com/resources/assets/public/img/flags/it.png ITA
https://kalkinemedia.com/resources/assets/public/img/flags/nl.png NLD
https://kalkinemedia.com/resources/assets/public/img/flags/pt.png PRT
https://kalkinemedia.com/resources/assets/public/img/flags/se.png SWE
https://kalkinemedia.com/resources/assets/public/img/flags/gr.png GRC
https://kalkinemedia.com/resources/assets/public/img/flags/in.png IND
https://kalkinemedia.com/resources/assets/public/img/flags/pl.png POL
https://kalkinemedia.com/resources/assets/public/img/flags/br.png BRA
https://kalkinemedia.com/resources/assets/public/img/flags/za.png ZAF
https://kalkinemedia.com/resources/assets/public/img/flags/ru.png RUS
https://kalkinemedia.com/resources/assets/public/img/flags/cn.png CHN
https://kalkinemedia.com/resources/assets/public/img/flags/ae.png UAE
Kalkine Media ASX Share Market News & Research
Sponsored

Radiopharm (ASX:RAD) secures key isotope from ANSTO for lung cancer trial

November 23, 2022 01:09 PM NZDT | By Aditi Sarkar
Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp
Radiopharm (ASX:RAD) secures key isotope from ANSTO for lung cancer trial
Image source: © Terovesalainen | Megapixl.com

Recent News

thumbnail

Canned Lamb Market Revenue to Boost Cross $2.4 Billion, At a Booming 4...

thumbnail

Spacesuit Market Size Worth USD 1.5 Billion Globally, by 2031 | Spacex...

thumbnail

Farzin Irani Appointed Regional Director – APAC and Joins Senior Manag...

thumbnail

hunterAI Named in Gartner Market Guide for Healthcare Provider Supply...

Highlights

  • Radiopharm has executed a deal with ANSTO to secure the supply of Lutetium-177 (Lu-177).
  • The company will use the key isotope in combination with its propriety nanobody in a Phase I therapeutic dose escalation trial in patients with non-small cell lung cancer.
  • Radiopharm expects to start the Phase I dose escalating clinical trial in the first quarter of 2023.

Australia-based developer of radiopharmaceutical products, Radiopharm Theranostics (ASX:RAD) has taken another important step in its clinical journey towards cancer treatment.

The company has inked an agreement with Australia's Nuclear Science and Technology Organisation (ANSTO) for the supply of Lutetium-177 (Lu-177).

ANSTO is the home of Australia's most significant landmark and national infrastructure for research. The organisation operates OPAL, which is one of the world’s most modern nuclear research reactors.

Lu-177 - Key isotope for Radiopharm’s Phase I therapeutic trial

Radiopharm needs Lu-177, an isotope non-carrier-added lutetium-177, for its trials in Australia.

The isotope is planned to be used in combination with Radiopharm's propriety nanobody in a Phase I therapeutic dose-escalation trial. The clinical trial would focus on patients with non-small cell lung cancer.

Radiopharm plans to commence the trial in Q1 2023 in partnership with GenesisCare and ANSTO.

The agreement will come into effect from 01 December 2022.

Shaun Jenkinson, CEO of ANSTO, said “We are excited that the isotopes we will supply to Radiopharm Theranostics will go toward expanding this vision at it seeks to revolutionise cancer treatment.”

This is what Radiopharm CEO and Managing Director has to say 

© 2022 Kalkine Media®, Data and image source: Company update

Inside Radiopharm’s key agreements during 2022

This year, Radiopharm has secured several key agreements for the smooth running of its clinical trials.  

© 2022 Kalkine Media®, Data source: Company update

RAD shares were trading at AU$0.120 apiece in the early hours of 23 November 2022.

Disclaimer

The content on this website, including, but not limited to, any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (“Content”) is a service provided by Kalkine Media New Zealand Limited (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide financial advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests users seek financial advice from a financial advice provider, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all liability to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without any express or implied warranties of any kind. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit a source wherever it is indicated or is found to be necessary or desirable.

Sponsored Articles

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.